The Immunotherapy of Cancer Conference (ITOC) is a European meeting providing a global platform for translational research in the field of immuno-oncology as well as a forum for discussion of early clinical translation and to address its unique challenges.

This meeting will bring together a diverse group of basic, translational and clinical researchers including those from academia, industry and government to cooperatively discuss the mechanistic basis of failed immunotherapy, and novel approaches to activating the immune system, in order to provide insight for future clinical applications of novel approaches and optimal combination therapies.

Register for On Demand access: https://hubs.la/Q0445qFR0

The 2026 SITC Spring Scientific will bring together experts in cell therapy, drug development, and immuno-oncology to address the timely topic of next-generation cellular therapies, T cell engagers, and combination therapies to treat cancer.

The highlight of the Summit4CI is an annual conference that brings together up to 350 leading scientists, clinicians, students and economists with representatives from industry, patient groups, charities and government. The conference explores the latest progress in cancer immunotherapy from scientific, clinical, industry and patient perspectives, through internationally recognized speakers, scientific presentations, poster sessions, panel discussions an Oxford-style debate and networking opportunities.

The AACR Annual Meeting is the focal point of the cancer research community, where scientists, clinicians, other health care professionals, survivors, patients, and advocates gather to share the latest advances in cancer science and medicine. From population science and prevention; to cancer biology, translational, and clinical studies; to survivorship and advocacy; the AACR Annual Meeting highlights the work of the best minds in cancer research from institutions all over the world.

Every year, the CIMT Annual Meeting connects the global cancer immunotherapy community in the heart of Europe. As the largest not-for-profit annual meeting in Europe focused on cancer immunotherapy research and development, CIMT invites international participants for high-level scientific exchange, collaboration, and education.

This Keystone Symposia Conference will explore interactions between tumor cells and their surrounding microenvironment, examining both tumor-intrinsic and -extrinsic signaling programs that influence cancer progression and systemic host responses such as aging, cachexia, obesity, and immunity. The program will highlight innovative experimental and computational tools to study the tumor microenvironment (TME), with a focus on identifying tumor vulnerabilities, new therapeutic targets, and methods for patient stratification. A hands-on “data jamboree” workshop will showcase analytical tools developed by the NCI Human Tumor Atlas Network (HTAN) to analyze the TME.

This meeting will bring together experts in cancer biology, immunology, computational biology, chemical biology, and beyond, to catalyze cross-disciplinary collaborations and insights with clinical impacts.

This Aegean conference on cytokine signaling in cancer aims to bring together outstanding experts in fundamental and translational cytokine research to foster collaboration and knowledge in understanding cancer etiology, pathogenesis, and response to immunotherapies, along with devising novel cytokine-specific diagnostic approaches and treatment modalities.

St Jude Children’s Research Hospital and Technical University of Munich are proud to host the ‘ImmunoMemphis’ symposium where the immunological community will come together in Memphis, Tennessee to discuss fundamental mechanisms of T cell differentiation, and how these insights can be translated into durable immunotherapies for cancer and chronic viral infections.

Topics will include conceptual and technical advances that are reshaping our understanding of T cell immunological memory, current barriers in establishing T cells with tissue/tumor-homing properties, resistance to local-immunosuppression, and the capacity for establishing disease control with long-term immunological protection.

The 2026 ASCO Annual Meeting Program will feature over 200 sessions complementing Dr. Eric Small’s Presidential theme, The Science and Practice of Translation: Improving Cancer Outcomes Worldwide.

Chair/s for this conference: Greg Delgoffe - University of Pittsburgh; Nikhil Joshi - Yale University; Amanda Lund - NYU Langone Health.

Registration closes April 16, 2026

This year’s program will continue that tradition of innovation by examining the structural and functional dynamics of immunoreceptors, their mechanisms of activation and regulation, and translational research driving new immunotherapeutic strategies. As key molecules that regulate immune responses, research into immunoreceptors has yielded precise and effective therapies, including checkpoint inhibitors, CAR-T cell therapies, and novel monoclonal antibodies.

SITC 2026 provides a multidisciplinary educational and interactive environment focused on improving outcomes for cancer patients by incorporating strategies based on basic and applied cancer immunotherapy.

This conference will gather immunologists, oncologists, technologists, and engineers from academia and industry focused on basic research and clinical translation with the goal of fostering interactions among stakeholders that do not normally interact. To achieves this the conference program will feature new approaches targeting innate cells, application of model systems that replicate aspects of human cancer to inform new therapeutic approaches, the application of protein engineering and materials science to bridge gaps in treatment along with the latest innovations regarding T cell state regulation and application of checkpoint therapy in the clinic.

Early Registration Deadline: November 23, 2026
Scholarship Deadline: September 29, 2026
Short Talk Abstract Deadline: September 29, 2026
Poster Abstract Deadline: January 4, 2027

Cochairs

Nina Bhardwaj, Icahn School of Medicine at Mount Sinai, New York, New York
Antoni Ribas, UCLA Jonsson Comprehensive Cancer Center, Los Angeles, California